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Increased sensitivity for detecting malaria
parasites in human umbilical cord blood using
scaled-up DNA preparation
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Abstract
Background: All mothers donating umbilical cord blood units to the NHS cord blood bank undergo an
assessment for the likelihood of prior exposure to malaria infection. Those deemed at risk due to a history of travel
to, or residence in, malaria endemic regions are screened serologically to detect anti-malaria antibodies. A positive
result excludes the use of the cord blood for transplant therapy unless a risk assessment can ensure that malaria
transmission is extremely unlikely. This paper details the screening of cord blood units from malaria serology
positive mothers to detect malaria parasite DNA using a highly sensitive nested PCR.
Methods: Uninfected blood from a healthy volunteer was spiked with known quantities of malaria parasites and 5
millilitre and 200 microlitre aliquots were subjected to DNA extraction using QIAamp DNA maxi and DNA mini kits
respectively. Nested PCR, to detect malarial SSU rRNA sequences, was performed on the purified DNA samples to
determine the limit of detection for this assay with both extraction methodologies. Following assay validation, 54
cord blood units donated by mothers who were positive for anti-malaria antibodies were screened by this
approach.
Results: When DNA was purified from 5 millilitres of blood it was possible to routinely detect as few as 50 malaria
parasites per millilitre using nested PCR. This equates to a significant increase in the sensitivity of the current gold
standard nucleic acid amplification technique used to detect malaria parasites (routinely performed from > 200
microlitre volumes of blood). None of the 54 donated cord blood units from serology positive mothers tested
positive for malaria parasites using this scaled up DNA preparation method.
Conclusion: Serological testing for malaria parasites may be overly conservative, leading to unnecessary rejection
of cord blood donations that lack malaria parasites and which are, therefore, safe for use in stem cell therapy.
Background
Umbilical cord blood units (CBUs) are a rich source of
stem cells. An ever increasing number of conditions
have been treated using cord blood stem cells, with an
estimated 20,000 people having received such therapy to
date for conditions such as malignancies, immunodefi-
ciencies [1], metabolic disorders [2], bone marrow fail-
ure [3] and haemoglobinopathies [4]. At present, for
many ethnic minority patients in the UK, the likelihood
of finding a suitably HLA matched donor is significantly
decreased due to the predominance of Caucasian donors
[5]. Furthermore, matching of ethnicity has been shown
to have a significantly beneficial effect on the outcome
of unrelated cord blood transplantation [2]. Due to the
requirement for immune suppression with current allo-
graft technology all CBUs must be screened (directly or
indirectly) for pathogens before use. Transplacental
transmission of malaria has been documented in areas
which are endemic for malaria [6,7]. Those mothers
donating CBUs who have visited or lived in malaria
endemic countries or have had a confirmed episode of
malaria in the past are therefore screened serologically
using a commercially available enzyme immunoassay
(Malaria Ab EIA, Lab 21, Cambridge, UK) to look for
the presence of anti-malaria antibodies. A positive result
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excludes the use of the cord blood for transplant ther-
apy. It is known that anti-malaria antibodies may be
present long after the clearance of a malaria infection
[8,9]. Although one of the antigen components (MSP2)
in the assay is targeted by antibodies with a very short
half life in children [10], antibodies to the other antigen
component (MSP1) may be very long lived [11]. There
remains the possibility, therefore, that serological testing
results in the unnecessary rejection of CBUs which do
not contain malaria parasites. This is especially proble-
matic for members of ethnic minorities, given the likeli-
hood of serology positive mothers belonging to these
groups.
Currently, nested PCR [12] is the most sensitive and
robust nucleic acid amplification technology (NAAT)
available to screen blood for the presence of malaria
parasites and, with a published sensitivity of 400 para-
sites per ml, is significantly more sensitive than light
microscopy [13]. Current protocols generally use small
volumes of blood (50-200 μl) with commercial extrac-
tion kits (e.g. QIAamp mini kit) to purify nucleic acids
prior to testing by nested PCR. Using QIAamp maxi kits
for isolating DNA from 5 ml of cord blood it was possi-
ble to reliably detect as few as 50 parasites per milliliter
of blood in spiked blood samples. Analysis of 54 CBUs
from serologically positive mothers failed to detect
malaria parasites at levels above this threshold.
Methods
Assay validation was performed with in vitro cultured
parasites of the 3D7 strain of Plasmodium falciparum.
Parasites were synchronized using sorbitol to remove all
forms other than ring-stage (early) trophozoites [14]. The
purified early trophozoites were washed and then re-sus-
pended in 1 ml of fresh blood, collected in EDTA from
an uninfected volunteer. This produced a 3% parasitae-
mia, which was determined by microscopy using thin
blood films stained in Rapid Fields. Assuming a starting
red cell density of 5 × 109 per ml, this equates to 1.5 ×
108 parasites per ml. Serial dilutions in the same unin-
fected blood were made to produce samples with effec-
tive parasite densities of 5000, 500 and 50 parasites per
ml. DNA (both human and parasite) was purified from 5
ml and 200 μl of frozen blood using the QIAamp DNA
Blood maxi kit and the QIAamp DNA blood mini kit
respectively (Qiagen, Hilden, Germany), as per manufac-
turer’s instructions. For the 5 ml and 200 μl samples the
final elution used 1 ml and 100 μl of buffer EB. From
each eluate, 5 μl was analysed using a nested PCR
approach as per published methods to amplify P. falci-
parum, Plasmodium vivax, Plasmodium malariae and
Plasmodium ovale small sub-unit ribosomal RNA
sequences [12]. Plasmodium ovale is best described as
two sister species of which can be differentiated by use of
the nested PCR; DNA from the so-called variant type
(recently named Plasmodium ovale wallikeri) does not
amplify with this assay [15]. To overcome this, an alter-
native PCR was carried out combining the first round of
the nested PCR with a second round of PCR using alter-
native PCR primers [16]. The resultant assay amplifies
both P. ovale curtisi and P. ovale wallikeri reliably. To
ensure the spiked blood samples contained the correct
density of parasites, the QIAamp DNA mini eluates were
titred using a real-time PCR assay against DNA from 200
μl aliquots of a ten fold dilution series of the WHO inter-
national standard for P. falciparum [17,18]. All PCRs
were carried out at the Parasite Reference Laboratory, a
fully CPA accredited lab, which routinely carries out
malaria diagnostics.
Following assay validation, DNA was extracted from 54
umbilical CBU donations from mothers who were posi-
tive for malaria antibodies by the EIA assay and the DNA
was amplified to determine the presence or absence of
Plasmodium species DNA as above. The study was
granted ethical approval by the Research Ethics Commit-
tee (REC) of University College London Hospitals (REC
reference 07/Q0505/60) and all mothers gave written
informed consent that CBUs could be used for research
if they were rejected for use in transplant therapies.
Results
In validation experiments, uninfected umbilical cord
blood spiked with cultured malaria parasites was routi-
nely positive by amplification for samples with parasite
densities at or above 500 parasites per millilitre. This was
true for DNA extracted from either 5 ml or 200 μl of this
blood. With spiked blood containing 50 parasites per
millilitre, positive amplification was achieved in 85% (17/
20) of PCR reactions using DNA prepared from 5 ml of
blood. By contrast, only 30% (6/20) of PCR reactions
showed positive amplification when using DNA prepared
from a 200 μl aliquot. Thus, at this level of parasite den-
sity there is a significant improvement in the rate of
detection when using the larger blood volume for DNA
preparation (P < 0.001, Yates corrected Chi squared). No
amplification was seen with DNA preparations from
uninfected adult human peripheral blood or umbilical
cord blood spiked with lower levels of parasites.
None of the 54 CBUs analysed using manual extrac-
tion of 5 ml by the maxi preparation method showed
the presence of detectable parasite DNA from any of
the five parasite species tested in the assay. All positive
control DNAs from infected patient samples amplified
correctly in these assays.
Discussion
The use of larger blood volumes for DNA preparation
offers a significant improvement in the limit of
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sensitivity of detection for the diagnosis of P. falciparum
parasites using nested PCR. This can be readily
explained by the density of parasite genomes in the
resultant eluates. 5 ml of blood with a parasite density
of 50 parasites per ml will contain approximately 250
parasites. Assuming a 100% recovery of DNA in the 1
ml eluate, then on average there will be 1.25 parasites
genomes within the 5 μl of eluate assayed. When only
200 μl of blood is extracted using Qiagen miniprep kits,
such a parasite density would result in at best 0.5 para-
site genomes within an amplification reaction, even
where 100 μl of elution buffer is used to purify DNA in
order to maximize DNA concentration. Even with the
multi copy target used in this assay, 0.5 parasite gen-
omes appears to be too little DNA to support reliable
amplification. In addition to this increased DNA con-
centration, the ability to sample a much larger volume
of blood will decrease sampling variability and also serve
to increase the reliability of the assay.
Within the literature there are reports of amplification
from blood samples containing as few as 20 parasites
per ml [16]. It is hard to envisage how such amplifica-
tion could be achieved using a standard QIAamp mini
DNA extraction protocol, as is in usage in many diag-
nostic laboratories. Extraction of 200 μl samples con-
taining 20 parasites per ml will produce eluates
containing at best only 0.04 parasites genomes per μl.
Even where 5 μl of DNA is used in a PCR reaction, this
would equate to only 0.12 parasite genomes per reaction
and it is surprising that such a concentration could pro-
duce reliable amplification with a single round PCR.
Indeed, in a recent report on different PCR methodolo-
gies using QIAamp mini DNA extraction protocol inves-
tigators were unable to amplify less than 400 parasites
per ml routinely [13]. It is possible that incorrect esti-
mation of parasite density by slide microscopy may
result in the reporting of inaccurate limits of detection
in the literature. Titration of DNA samples against the
internal standard for P. falciparum using real-time
amplification allows an unbiased estimation of parasite
density and therefore a greater confidence of the limits
of detection of a given assay. Our reported limits of
detection for nested PCR using QIAamp mini kit
derived DNA are also in good accordance with a com-
parable study [13].
Even though the extraction of 5 ml blood volumes
represents a significant improvement in diagnostic sensi-
tivity, it most likely that the time and costs involved in
the manual extraction of large volumes of blood and the
subsequent analysis by nested PCR would preclude such
a technology for the routine diagnosis of malaria. Nor
could such an approach feasibly be applied to the wide
spread identification of very low level infections as part
of a malaria elimination programme, as again the cost in
materials and personnel-hours would be prohibitive.
However, for applications such as the screening of mate-
rial for transplantation, where it is essential that sensi-
tivity is maximized to prevent the transference of
parasites into an immuno-compromized person, the
assay could prove a valuable method to help ensure the
safety of donations from Ab-positive individuals.
From studies within locations endemic for malaria, the
probability of detecting malaria parasites within CBUs
has been shown to be significantly increased by a high
density of parasites in the mother’s peripheral blood and
intervillous placental blood. Within a cohort of Kenyan
women, those with peripheral blood parasite densities in
the highest tercile (geometric mean of 1,226,016 para-
sites per ml) had a three fold higher probability of hav-
ing malaria parasites in their cord blood (probability of
having malaria parasites = 0.43) compared to the middle
tercile (probability of malaria parasites = 0.13, geometric
mean = 13,368 parasites per ml). However, a lack of
detectable parasites in the peripheral blood is not refrac-
tory to the presence of parasites in the cord blood (6.5%
of women who had no detectable circulating parasites
had parasites in their cord blood) [7]. It is therefore
necessary to screen the cord blood directly rather than
maternal peripheral blood to be certain that parasites
are absent from a CBU. Within this study of 54 umbili-
cal CBU donations, even with the use of an assay with
significantly increased sensitivity, we found no evidence
of infection with malaria parasites. We conclude that it
is highly unlikely that any of the donations had a para-
site density of greater than 50 parasites per millilitre
(0.05 parasites per μl). If this is generally applicable to
donations from serologically positive mothers then it
may be that the majority of malaria Ab-positive CBU
donations received in the UK, but deemed unsuitable
for transplant, actually lack malaria parasites. This unne-
cessarily reduces the availability of an already scarce
resource. It is worth noting that the likelihood of trans-
placental transmission may be significantly increased in
cohorts tested in malaria endemic locations (compared
to the 54 CBUs within our study) due to infection with
P. falciparum variants known to preferentially target
pregnant women and establish placental infections
[19,20]. However, among UK based mothers with
detectable malaria antibodies, the likelihood of infection
with such variants would be very low if the causative
episode(s) of malaria infection occurred before preg-
nancy. In such cases, a negative PCR result would sup-
port the use of these units for transplant therapies as
posing a very low risk for malarial transmission. How-
ever, if potential exposure to malaria parasites occurred
during pregnancy a positive maternal antibody test even
with a negative PCR result would require further risk
assessment.
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Given that this assay requires 5 ml of blood it may be
unrealistic to run the assay routinely on all CBU dona-
tions from mothers potentially exposed to malaria, but
as standard practice in the NHS cord blood bank is to
collect blood samples for red cell grouping from red cell
“waste” product removed during the processing of
CBUs, an additional 5 ml sample could be taken for
malaria PCR testing in the event of a positive malaria
antibody result. Even where CBUs are not to be tested
directly, the risk of malaria infection from serologically
positive mothers needs to be re-evaluated in the light of
this work. This would be especially relevant in the cases
of recipients suffering from illnesses with high childhood
mortality, and where prognosis has been shown to be
dramatically improved following transplantation of
umbilical cord blood stem cells [2].
Conclusion
Malaria antibody positivity in a UK mother who donates
cord blood should not be an automatic contraindication
to its subsequent use in stem cell transplantation.
Transplantation could proceed after an individual risk
assessment, preferably including NAAT, with careful
monitoring of the recipient.
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